Caribou Biosciences(NASDAQ) CRBU

Caribou Biosciences develops cell therapies for cancer patients who have not responded to other treatments. Its main products use gene editing to create ready-to-use immune cells from healthy donors. These therapies aim to help people with blood cancers and solid tumors access new treatment options.

Products and Services

• CB-010 (Anti-CD19 CAR-T): Off-the-shelf cell therapy for B cell non-Hodgkin lymphoma; in early clinical trials.
• CB-011 (Anti-BCMA CAR-T): Cell therapy for multiple myeloma, a type of blood cancer; in early clinical trials.
• Licensing Revenue: All reported revenue in 2025 came from licensing and collaboration agreements with partners such as Pfizer.
• Discontinued Programs: CB-012 (for acute myeloid leukemia) ended in 2025 after strategic review.
• Research Collaboration: Partnership with AbbVie to develop new cell therapies using Caribou’s technology.

Growth and Expansion

• Formed a key partnership with AbbVie to co-develop cell therapies (year not specified).
• Signed licensing agreements with Pfizer and Edge Animal Health; in Q2 2025, revenue was generated from Pfizer and other licensees, but not from Edge Animal Health.
• Discontinued two clinical and one preclinical program in Q2 2025 to focus on lead products.
• Reduced workforce by 32% and rationalized facilities in Q2 2025 to cut costs.
• In Q2 2025, 37.7% of licensing revenue was generated from outside the United States.

What Makes Caribou Stand Out

Caribou uses a proprietary gene-editing platform called chRDNA to create precise, off-the-shelf cell therapies. Its approach allows for rapid treatment using healthy donor cells, rather than relying on a patient’s own cells. The company’s focus on allogeneic (donor-derived) therapies aims to make advanced cancer treatments more widely accessible.

Five Things You Need to Know

• Revenue was $2.7 million in Q2 2025, down 23% from $3.5 million in Q2 2024.
• All revenue comes from licensing and collaboration, not product sales.
• Net loss was $54.1 million in Q2 2025, up 43.5% from $37.7 million in Q2 2024.
• Cash and marketable securities totaled $183.9 million as of June 30, 2025.
• Top three licensees made up 82.6% of Q2 2025 revenue.

Bottom Line

Caribou has narrowed its focus to two main cancer therapy programs and reduced costs to extend its resources. The company remains in early clinical stages, relying on licensing revenue and partnerships to fund its operations.